A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,668 shares of PCRX stock, worth $29,273. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,668
Previous 1,390 20.0%
Holding current value
$29,273
Previous $39,000 35.9%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$11.7 - $28.46 $3,252 - $7,911
278 Added 20.0%
1,668 $25,000
Q2 2024

Jul 30, 2024

SELL
$25.5 - $31.51 $502,018 - $620,337
-19,687 Reduced 93.41%
1,390 $39,000
Q1 2024

May 01, 2024

SELL
$27.7 - $35.48 $24,819 - $31,790
-896 Reduced 4.08%
21,077 $615,000
Q4 2023

Jan 24, 2024

BUY
$26.32 - $34.31 $31,215 - $40,691
1,186 Added 5.71%
21,973 $741,000
Q3 2023

Oct 26, 2023

BUY
$30.68 - $40.09 $1,534 - $2,004
50 Added 0.24%
20,787 $637,000
Q2 2023

Aug 10, 2023

SELL
$36.12 - $47.5 $3,359 - $4,417
-93 Reduced 0.45%
20,737 $830,000
Q1 2023

May 04, 2023

SELL
$35.53 - $43.38 $994 - $1,214
-28 Reduced 0.13%
20,830 $850,000
Q4 2022

Feb 09, 2023

BUY
$38.19 - $57.45 $33,530 - $50,441
878 Added 4.39%
20,858 $805,000
Q3 2022

Nov 10, 2022

BUY
$51.24 - $58.89 $295,398 - $339,500
5,765 Added 40.56%
19,980 $1.06 Million
Q2 2022

Jul 26, 2022

BUY
$51.49 - $81.64 $731,930 - $1.16 Million
14,215 New
14,215 $829,000
Q1 2018

May 10, 2018

SELL
$29.98 - $46.35 $1.14 Million - $1.76 Million
-37,895 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$31.85 - $46.95 $1.21 Million - $1.78 Million
37,895
37,895 $1.73 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $804M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.